(3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide

(3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide

Intermediate for Vorapaxar. Vorapaxar (trade name: Zontivity) is a thrombin receptor (protease-activated receptor, PAR-1) antagonist. Vorapaxar is a new anti-platelet drug that and is used for persons with a history of myocardial infarction (heart attack) or persons with peripheral arterial disease. Vorapaxar has been approved by the U.S Food and Drug Administration on May 5, 2014.

Specifications

Product Name:                  (3R,3aS,4S,4aS,7R,9aR)-3-Methyl-7-nitro-1-oxo-N,N-diphenyl-1,3,3a,4,4a,5,6,7,8,9a-decahydronaphtho[2,3-c]furan-4-carboxamide

Synonyms:                         N/A

CAS Number:                     900186-72-3

Molecular Weight:            446.5018

Molecular Formula:          C26H26N2O5

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               O=C(O[C@@H]3C)[C@]([C@]3([H])[C@H]2[C@](N(C5=CC=CC=C5)C4=CC=CC=C4)=O)([H])C=C1[C@@]2([H])CC[C@@H]([N@

  • $1,662.00
  • Ex Tax: $1,662.00

Available Options